HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Dose-intense ifosfamide/doxorubicin/cisplatin based chemotherapy for osteosarcoma in adults.

Abstract
The efficacy of neoadjuvant and adjuvant chemotherapy has been clearly established in the treatment of osteosarcoma; however, the most active regimen remains to be identified. This prospective study evaluated the efficacy and toxicity of a dose-intense ifosfamide, doxorubicin, and cisplatin-based neoadjuvant regimen in adults with osteosarcoma. We prospectively treated 20 patients with osteogenic sarcoma with two cycles of ifosfamide/doxorubicin followed by two cycles of doxorubicin/cisplatin every 2 weeks. Surgical specimens were analyzed for percent tumor necrosis. Patients who demonstrated a "good response" (GR) to chemotherapy received the same combination postoperatively at a lower dose rate. Patients who demonstrated a "poor response" (PR) received four cycles of high-dose methotrexate alternating with two cycles of ifosfamide/etoposide and two cycles of cisplatin/etoposide after the surgery. Neoadjuvant chemotherapy was well tolerated with moderate hematologic toxicity. Twelve of 19 evaluable patients (63%) were treated according to the GR arm and 7 according to the PR arm. At median follow-up of 5.5 years, disease-free survival (DFS) and overall survival (OS) are 68% and 74%, respectively. Patients treated on the GR arm had DFS and OS of 75% and 83%, respectively, whereas patients on the PR arm had DFS and OS of 57%. Intensive neoadjuvant chemotherapy is effective and moderately well tolerated in patients with de novo osteosarcoma. The outcome data suggest that lack of a near complete response to preoperative chemotherapy reflects inherent biologic resistance to chemotherapy and hence a poor prognosis.
AuthorsShailesh J Patel, James W Lynch Jr, Thomas Johnson, Robert R Carroll, Cynthia Schumacher, Susanne Spanier, Mark Scarborough
JournalAmerican journal of clinical oncology (Am J Clin Oncol) Vol. 25 Issue 5 Pg. 489-95 (Oct 2002) ISSN: 0277-3732 [Print] United States
PMID12393991 (Publication Type: Clinical Trial, Journal Article)
Chemical References
  • Doxorubicin
  • Cisplatin
  • Ifosfamide
Topics
  • Adult
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Bone Neoplasms (drug therapy, pathology, surgery)
  • Cisplatin (administration & dosage)
  • Doxorubicin (administration & dosage)
  • Histiocytoma, Benign Fibrous (drug therapy, pathology, surgery)
  • Humans
  • Ifosfamide (administration & dosage)
  • Middle Aged
  • Neoadjuvant Therapy
  • Osteosarcoma (drug therapy, secondary, surgery)
  • Prospective Studies
  • Survival Analysis

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: